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Purpose of the study
The aim of this analysis was to compare the incidence of
opportunistic infections (OIs) and death in immunocom-
promised patients with a CD4 count ≤200 cells/mm3
across those with:
• viral load (VL) <500 copies/mL whilst on combination
antiretroviral therapy (cART) (VL <500 c group)
• VL ≥500 copies/mL whilst on cART (VL ≥500 c)
• VL ≥500 copies/mL whilst off all ART (VL ≥500 nc).
Methods
Patients contributed to the person-years at risk if the most
recent CD4 count was ≤200 cells/mm3, and if VL was
measured in the 6 months before the CD4 count. All
patients contributing at least one month's follow-up were
included. Multivariable analyses were adjusted for current
CD4 count, VL, calendar time of follow-up, age, whether
or not ART-naive, ethnicity, risk group, hepatitis B and C
status, and for death rates, prior AIDS diagnosis.
Summary of results
4,886 patients were included contributing 7,625 person-
years of follow-up (PYFU), during which time 741 OIs
and 449 deaths occurred (Table 1). Patients in the VL
<500 c group started cART a median time of 1.5 (IQR
0.6–3.7) years prior to baseline, while of 3,524 patients in
the VL ≥500 c group, 1,298 (37%) had previously been
virologically suppressed, a median time of 8 (IQR 4–18)
months before baseline. 605 patients (37%) in the VL
≥500 nc group had never started cART, and among those
that had, the median time since stopping cART was 1.1
(IQR 0.5–C5.4) months.
After adjustment, compared to the VL <500 c group, there
was a 2-fold increased incidence of OIs in the VL ≥500 c
group and a 4-fold increased incidence in the VL ≥500 nc
group. There was a much higher crude death rate in the VL
≥500 nc group compared to the other two groups (Table).
After adjustment, the death rate in the VL ≥500 nc group
remained over eight times higher than both the VL <500 c
and VL ≥500 c groups. When comparing the VL <500c and
VL ≥500 c groups, the lower death rate observed in the VL
≥500 c group was found to be mostly explained by differ-
ences in cART regimen.
Conclusion
Achieving virological suppression in immunocompro-
mised patients is important for reducing the risk of OIs.
Patients on cART have a much lower risk of death than
those not receiving cART, regardless of viral suppression.
Part of this difference in risk of death may be due to ter-
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minally ill patients being taken off cART and warrants fur-
ther analysis of deaths caused by OIs and deaths caused by
non-OIs.
Table 1: 
VL <500 c VL ≥500 c VL ≥500 nc
PYFU 3507 4274 934
Number of OIs 104 414 223
Crude event rate (95% CI) 3.0 (2.4–3.5) 9.7 (8.8–10.6) 23.9 (20.8–27.0)
Adjusted rate ratio (95% CI) 1.0 1.9 (1.5–2.4) 4.3 (3.3–5.7)
5 most commonly occurring OIs, n (% of all OIs):
Oesophageal candidiasis 11 (11%) 70 (17%) 50 (22%)
PCP 6 (6%) 11 (3%) 21 (9%)
Cytomegalovirus (CMV) chorioretinitis 2 (2%) 38 (9%) 11 (5%)
HIV wasting syndrome 6 (6%) 27 (7%) 11 (5%)
Mycobacterial tuberculosis, pulmonary 6 (6%) 22 (5%) 13 (6%)
Number of deaths 86 104 259
Crude event rate (95% CI) 2.5 (1.9–3.0) 2.4 (2.0–2.9) 27.7 (24.4–31.1)
Adjusted rate ratio (95% CI) 1.0 0.7 (0.5–1.0) 8.5 (6.4–11.1)
Median (IQR)
Calendar time of follow-up 09/01 (06/99-06/04) 04/00 (07/98-02/03) 01/01 (03/99-08/03)
CD4 count (/cells/mm3) 148 (109–178) 118 (61–160) 108 (50–158)
VL (log10 copies/mL) 1.7 (1.7–2.3) 4.4 (3.6–5.0) 4.9 (4.3–5.4)Page 2 of 2
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